AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19965519
Drug: Previous interferon-beta
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous interferon-beta preparation (subcutaneous)
Trial: 11187583
Drug: In-patient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-patient treatment
Trial: 17978324
Drug: Specialist out-patient
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specialist out-patient treatment
Trial: 20334748
Drug: General CAMHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General CAMHS treatment
Trial: 9494148
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg orally per day
Trial: 9494148
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg orally per day
Trial: 9494148
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg orally twice a day
Trial: 9494148
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg per day (maintenance)
Trial: 9494148
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice a day (maintenance)
Trial: 8307222
Drug: Acetylsalicylic acid/dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid/dipyridamole (50 mg/400 mg daily)
Trial: 30884964
Drug: 3‐OHB infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐OHB infusion
Trial: 27798513
Drug: Everolimus (EVL)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVL) with target trough level (Ctrough, 3‐8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2‐5 ng/mL)
Trial: 22582933
Drug: Psychotropic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medications (specific drugs not mentioned)
Trial: 19545249
Drug: MAP0004 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP0004 0.5 mg
Trial: 19545249
Drug: MAP0004 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP0004 1.0 mg
Trial: 17314579
Drug: Ketamine (0.3%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.3%, 3 mL)
Trial: 11474143
Drug: 10% oral
RxNorm normalized name: Xylocaine 10% Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% oral glucose plus sucking
Trial: 9684795
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) injection, doses ranging from 5 to 320 microg/kg
Trial: 9684795
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) injection, doses < or = 20 microg/kg
Trial: 9684795
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) injection, doses > 20 microg/kg
Trial: 9684795
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) injection
Trial: 7766962
Drug: Food A
RxNorm normalized name: Food allergenic extracts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food A (3.12 g protein equivalent per 100 kcal)
Trial: 7766962
Drug: Food B
RxNorm normalized name: Real Food Blends Eggs Apples & Oats
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food B (2.74 g protein equivalent per 100 kcal)
Trial: 3144009
Drug: Protein supply
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supply (1 g protein/kg.d) and 1-carnitine (2 g/day)
Trial: 28343938
Drug: Testosterone (T)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) administered 2-3 hours prior to testing
Trial: 28343938
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 2-3 hours prior to testing
Trial: 23952097
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol (1 g IV every 8 hours for up to 24 hours)
Trial: 20147742
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model including large tumor cell fragments (L-TCF), age, hemoglobin and lactate dehydrogenase
Trial: 20147742
Drug: Models with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Models with S-TMP or CTC instead of L-TCF
Trial: 8157902
Drug: Lidocaine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (bolus i.v. of 1 mg/kg, followed by an infusion of 4 mg/min)
Trial: 8157902
Drug: Placebo (infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (infusion of saline at a rate of 1 mL/min)
Trial: 3530156
Drug: Chloroquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (10 mg base kg-1)
Trial: 3530156
Drug: Chlorproguanil (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorproguanil (1.5 mg kg-1)
Trial: 3530156
Drug: Placebo (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vitamin tablets)
Trial: 28884824
Drug: Anacetrapib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib (5 to 500 mg)
Trial: 2209920
Drug: Topical flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical flurbiprofen
Trial: 2651233
Drug: Nifedipine titrated
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine titrated to 60 mg/day
Trial: 793562
Drug: Dextroamphetamine sulfate,
RxNorm normalized name: Dextroamphetamine Sulfate, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate, 20 mg orally daily at 8 PM
Trial: 793562
Drug: Dextroamphetamine sulfate,
RxNorm normalized name: Dextroamphetamine Sulfate, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate, up to 40 mg orally
Trial: 23528880
Drug: Comprehensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive group program (psychoeducation, cognitive rehabilitation, cognitive behavioral therapy)
Trial: 8333598
Drug: Acute dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute dose of alcohol
Trial: 3447334
Drug: No antimetabolite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimetabolite treatment
Trial: 29414735
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with topical application of 50 μl toluidine blue (1 mg/ml) followed by laser irradiation using GaAlAs laser (630 nm, 10 mW/cm2)
Trial: 29414735
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) using diode laser (630 nm, 10 mW)
Trial: 29414735
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid application (dexamethasone 0.5 mg in 5 ml water mouthwash for 5 min)
Trial: 22906262
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg tamsulosin plus 0.5 mg dutasteride
Trial: 20876171
Drug: Nebulized epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized epinephrine plus oral dexamethasone
Trial: 2679853
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone alone
Trial: 12570938
Drug: Fasudil (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasudil (4.5 mg intracoronarily)
Trial: 12045833
Drug: Pyridostigmine (PYR)
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (PYR) 45 mg
Trial: 1991701
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) at a dose of 250 mg/m2/day for 12 weeks
Trial: 6127861
Drug: Nadolol 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 2% solution
Trial: 6127861
Drug: Timolol 0.25%
RxNorm normalized name: Timolol 0.25% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.25% solution
Trial: 19528154
Drug: 3 day
RxNorm normalized name: Kathro 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 day amoxicillin treatment
Trial: 19528154
Drug: 7 day
RxNorm normalized name: ZonaCort 7 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day amoxicillin treatment
Trial: 10193369
Drug: Pranlukast (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast (225 mg orally twice per day for four weeks)
Trial: 30571173
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (15 mg/wk)
Trial: 27475837
Drug: Icon condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icon condition (acetaminophen medications marked with an icon)
Trial: 24273022
Drug: Epratuzumab 360
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab 360 mg/m2
Trial: 24273022
Drug: Epratuzumab 720
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab 720 mg/m2
Trial: 22027612
Drug: Adaptol 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptol 500 mg, 2 times daily in addition to regular vasoactive treatment
Trial: 19006592
Drug: Colchicine mouthwash
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine mouthwash (2 mg daily for 5 days)
Trial: 14570343
Drug: Cefazolin plus
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin plus metronidazole (1 g cefazolin + 500 mg metronidazole)
Trial: 10817729
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of abacavir
Trial: 10817729
Drug: 0.7 g
RxNorm normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 g of ethanol per kg of body weight
Trial: 10817729
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of abacavir and 0.7 g of ethanol per kg
Trial: 8872401
Drug: Half-age energy
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-age energy dosing (7 J, 30% higher than titration estimates)
Trial: 8872401
Drug: Threshold titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold titration
Trial: 8872401
Drug: Half-age energy
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-age energy dosing
Trial: 1325574
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy (4 weeks or 8 weeks arm of treatment with ACT D and VCR)
Trial: 1325574
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy
Trial: 31425966
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT)
Trial: 30184600
Drug: Cytoreductive nephrectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive nephrectomy (CN) followed by interferon therapy
Trial: 24592952
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc gluconate (26 mg zinc twice daily for 14 days)
Trial: 23303986
Drug: Diazoxide 100
RxNorm normalized name: diazoxide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide 100 mg orally three times daily for 10 days
Trial: 8826981
Drug: Diazoxide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide treatment
Trial: 18038603
Drug: Standard antituberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antituberculosis therapy (Group 1)
Trial: 18038603
Drug: Standard antituberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antituberculosis therapy + paravasal lymphotrophic immunological correction (Group 2)
Trial: 18038603
Drug: Individual regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual regimens of antituberculous drugs (Group 3)
Trial: 15510746
Drug: FK‐506 eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK‐506 eyedrops (0.5 mg/ml) and TobraDex eyedrops
Trial: 7625343
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group fed formulas with protein-energy ratios of 3.73 g/MJ (1.56 g/100 kcal) from 8 to 27 days, decreasing to 2.99 g/MJ (1.25 g/100 kcal) from 84 to 111 days.
Trial: 357213
Drug: Ro 10‐9359
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 10‐9359 at 25 mg t.i.d.
Trial: 357213
Drug: Ro 10‐9359
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 10‐9359 at 50 mg b.i.d.
Trial: 18381513
Drug: Hypothermia (33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia (33 degrees C to 34 degrees C) for 72 hours with continuous morphine infusion
Trial: 18381513
Drug: Normothermia with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermia with continuous morphine infusion
Trial: 18381513
Drug: Hypothermia with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia with morphine infusion rate >10 microg/kg per h
Trial: 11910617
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein dietary supplements containing 118 mg of isoflavones (daidzein, genistein, glycitein and their respective glycosides)
Trial: 1282364
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha therapy (3 million units daily for the first month, then thrice weekly for 5 months)
Trial: 11145854
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha therapy
Trial: 1282364
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha therapy and Control group
Trial: 6374403
Drug: Triple intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple intrathecal (IT) chemotherapy (methotrexate, hydrocortisone, cytosine arabinoside) starting on day 1 of treatment (Arm 3)
Trial: 6374403
Drug: Triple IT
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple IT chemoprophylaxis during induction therapy (Arm 3)
Trial: 27358142
Drug: Lactulose oral
RxNorm normalized name: lactulose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose oral solution
Trial: 29669139
Drug: Spironolactone 100
RxNorm normalized name: spironolactone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 100 mg + furosemide 20 mg
Trial: 29669139
Drug: Nutritional counseling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional counseling to sodium-restricted diet plus placebo pill
Trial: 26482684
Drug: Modified Ranawat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Ranawat suspension
Trial: 17432691
Drug: Terazosin tablet
RxNorm normalized name: Terazosin Tablets
DrugBank: Terazosin (DB01162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terazosin tablet for 60 days
Trial: 10363731
Drug: bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion SR 150 to 400 mg/d
Trial: 10363731
Drug: sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline 50 to 200 mg/d
Trial: 7734255
Drug: 1% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% mepivacaine with adrenaline 40 ml, arm adducted
Trial: 7734255
Drug: 1% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% mepivacaine with adrenaline 40 ml, arm abducted
Trial: 7734255
Drug: 2% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% mepivacaine 20 ml mixed with contrast agent 20 ml, arm adducted
Trial: 7734255
Drug: 2% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% mepivacaine 20 ml mixed with contrast agent 20 ml, arm abducted
Trial: 6112602
Drug: D-penicillamine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine (600 mg daily)
Trial: 28594575
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (previously intensified treatment)
Trial: 19374211
Drug: Ephedrine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (Group E, n = 30, dose = 10 mg)
Trial: 19374211
Drug: Phenylephrine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (Group P, n = 30, dose = 80 microg)
Trial: 21959663
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (group II)
Trial: 11326796
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 900 mg/day
Trial: 3310631
Drug: Sucralfate therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate therapy, 1 g four times daily
Trial: 3310631
Drug: Sucralfate therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate therapy, 1 g twice daily to 1 g four times daily (long-term)
Trial: 29895557
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard treatment without empagliflozin)
Trial: 27183970
Drug: Vectra® 3D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vectra® 3D (54.45 mg/ml of dinotefuran, 396.88 mg/ml of permethrin and 4.84 mg/ml of pyriproxyfen)
Trial: 21040167
Drug: Post-transplantation dosing
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplantation dosing guided by a 2-hour (C(2) ) level (T2 group)
Trial: 21040167
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (control group)
Trial: 11305226
Drug: Intraoral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoral appliance therapy (daily use) during Phase I (6 months) and Phase II (6 months)
Trial: 11305226
Drug: Intraoral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoral appliance therapy (daily use) during Phase II (6 months)
Trial: 11305226
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (6 months prior to treatment)
Trial: 11305226
Drug: Phase I
RxNorm normalized name: Nuvelle TS Phase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I and Phase II of intraoral appliance therapy
Trial: 7949185
Drug: Standard Risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Risk Group (SRG) with reinduction therapy
Trial: 7949185
Drug: Standard Risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Risk Group (SRG) without reinduction therapy
Trial: 3190994
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 20 mg pholcodine
Trial: 3190994
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 60 mg pholcodine
Trial: 3190994
Drug: Chronic administration
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic administration of 20 mg pholcodine 8 hourly for 10 days
Trial: 30946381
Drug: Ropivacaine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine group (0.5% ropivacaine, 40 mL, n=69)
Trial: 30946381
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no analgesic, n=63)
Trial: 28968871
Drug: Standard-dose, egg‐grown,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose, egg‐grown, quadrivalent‐inactivated influenza vaccine (IIV4)
Trial: 25304132
Drug: Tralokinumab 300
RxNorm normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab 300 mg subcutaneously every 2 weeks for 12 weeks
Trial: 16861255
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide + 8 mg dexamethasone
Trial: 16861255
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg metoclopramide + 8 mg dexamethasone